by akronbiotech

Akron Biotech is committed to help defeat COVID-19 – Together we cure

Coronavirus disease 2019 (COVID-19) is a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms tend to appear 2-14 days after exposure to the virus and can range from mild to severe, with some patients requiring  hospitalization1.

In response to this global crisis, the scientific community has come together to develop vaccines, treatments, and improved diagnostic tools. As one of the leading manufacturers of GMP-compliant biologics and ancillary materials, we have been collaborating closely with several companies and academic institutions working tirelessly to develop novel treatments for this disease.

We have remained fully operational, taking the necessary precautions to make sure that, above all else, our employees and families remain safe. Moreover, we have adopted additional security measures in all of our manufacturing and logistics processes and are prioritizing the use of virus inactivated raw materials in our human blood-derived products, including our sera, plasma, and fibronectin.

If you are working on COVID-19 treatments, please reach out to us. Akron Biotech offers several products and services that can accelerate the development of your potentially life-saving treatments. Whether you are working to develop a cell therapy targeting COVID-19 and need materials for further manufacturing use, or are developing a biologic and need to source active pharmaceutical ingredients to support your efforts, please reach out. We are here to do everything we can to support the global community through these unprecedented times.

 

List of Akron’s Selected Products 

GMP Products

Interferons: 

cGMP Recombinant Human Interferon-beta 1A, rHu IFN-β1A

cGMP Recombinant Human Interferon-alpha 2A, rHu IFN-α2A

cGMP Recombinant Human Interferon-alpha 2B, rHu IFN-α2B

 

Virus-inactivated products:

cGMP Human Fibronectin Solution (Plasma Derived), Virus Inactivated

cGMP Human AB Serum (Converted from Plasma), Xeno-Free, Virus Inactivated

 

Proteins & Supplements:

cGMP Heparin Sodium Salt

 

Cytokines:

cGMP Recombinant Human Interleukin-2, rHu IL-2

cGMP Recombinant Human Interleukin-2 Solution, Pre-Filled Syringe

cGMP Recombinant Human Interleukin-4, rHu IL-4

cGMP Recombinant Human Interleukin-6, rHu IL-6

cGMP Recombinant Human Interleukin-7, rHu IL-7

cGMP Recombinant Human Interleukin-12, rHu IL-12

cGMP Recombinant Human Interleukin-15, rHu IL-15

cGMP Recombinant Human Interleukin-18, rHu IL-18

cGMP Recombinant Human Interleukin-21, rHu IL-21

cGMP Recombinant Human Erythropoietin, rHu EPO

cGMP Recombinant Human Stem Cell Factor, rHu SCF

cGMP Recombinant Human Epidermal Growth Factor, rHu EGF

cGMP Recombinant Human Transforming Growth Factor-beta, rHu TGF-ß 1

cGMP Recombinant Human Granulocyte-Colony Stimulating Factor, rHu G-CSF

cGMP Recombinant Human Granulocyte Macrophage Colony Stimulating Factor, rHu GM-CSF

cGMP Recombinant Human Platelet Derived Growth Factor-AA, cGMP rHu PDGF-AA

cGMP Recombinant Human Platelet Derived Growth Factor-BB, cGMP rHu PDGF-BB

 

 

Cryopreservation:

cGMP CryoSolve™, Single-Use Syringe

cGMP CryoSolutions™ 100%, DMSO Solution

cGMP CryoSolutions™ DX, 55% DMSO containing Dextran-40

cGMP CryoSolutions™ MC, 10% DMSO containing Methylcellulose

CryoNovo™ P24 (DMSO-free)

 

 

Services 

Aseptic Fill & Finish: Akron provides custom fill & finish services, filling single-use, closed packaging and custom kit options for customers in the cell and gene therapy and biopharmaceutical industries. We offer smart solutions that allow for more streamlined, consistent manufacturing with little to no manipulation, while reducing waste and costs of goods.

 

 

We are here for you:

If you are working on COVID-19 treatments and would like to learn more about our cGMP-compliant biologics and ancillary materials listed above, please email sales@akronbiotech.com and a member of our team will get back to you within 24 hours. 

References

  1. www.cdc.gov/coronavirus/2019-ncov/

 



Leave A Comment